COVID New York Update: Northwell Health's new PCR tests could make testing faster, cheaper

Health

WABC-TV 05 October, 2021 - 05:27pm 3 views

COVID NY: Northwell Health's new PCR tests could be a game changer

United Airlines put in one of the first COVID vaccine mandates, and now it is firing nearly 600 employees who have refused to comply with it.

Brian Laundrie's sister, Cassie, spoke out exclusively to ABC News in the wake of her brother's disappearance.

Read full article at WABC-TV

Eternals Fans Hyped for Movie With One Month to Go

PipelineReview.com 04 November, 2021 - 11:00pm

There's officially just one month until Eternals hits theaters, and fans of the feature are as excited as ever. Tuesday morning, Marvel Studios released an official "One Month" teaser, showing off even more footage from the upcoming Marvel Cinematic Universe blockbuster.

As you might expect, fans haven't been able to stop talking about the latest footage, which happened to be split amongst most members of the Eternals family. As such, the movie itself has been trending most of the day as fans recall their favorite part of the film's marketing cycle thus far.

Keep scrolling to see what people are saying.

THEY’RE COMING #Eternals pic.twitter.com/HOmf8sJkau

𝐖𝐄 𝐀𝐑𝐄 𝐈𝐍 𝐓𝐇𝐄 𝐄𝐓𝐄𝐑𝐍𝐀𝐋𝐒 𝐄𝐑𝐀 𝐍𝐎𝐖 🪐💫 | WE ARE ONE MONTH AWAY FROM THE RELEASE OF #ETERNALS 🔥🌏 pic.twitter.com/O5ssfVLytu

ONE MONTH TILL ETERNALS #ETERNALS pic.twitter.com/1xUGam2E4D

WE'RE ONLY ONE MONTH AWAY FROM #ETERNALS pic.twitter.com/Bz7YrLUTnR

Sersi using her powers in #Eternals pic.twitter.com/utmAgCZ5HZ

We’re officially one month away from #Eternals pic.twitter.com/m2ehULZ2Hi

Eternals is currently set for release on November 5th.

What'd you think of the final trailer of Chloe Zhao's Eternals? Let us know your thoughts either in the comments section or by hitting our writer @AdamBarnhardt up on Twitter to chat all things MCU!

Copyright 2021 ComicBook.com. All rights reserved.

J&J heats up RSV race with new vaccine data

marketscreener.com 06 October, 2021 - 09:02am

RSV, however, has never had a vaccine approved. Experimental candidates in the 1960s stimulated non-protective antibodies and a type of immune response that made the disease worse. Some treatments exist, such as the older antiviral ribavirin. A synthetic antibody called Synagis sold by Swedish Orphan Biovitrum can also prevent disease in high-risk babies.

But vaccines could help reduce cases and hospitalizations, and J&J's vaccine may eventually be a part of that immunization campaign, if further testing proves positive. 

The J&J vaccine is composed of two parts: the adenovirus vector used in its coronavirus vaccine but carrying genetic material that stimulates production of a protein which stimulates antibodies to RSV, and a synthetic version of the same protein. The company said the combined DNA and protein vaccine was created for "induction of a more optimal immune response."

A Phase 2 study called CYPRESS — data for which were released at the IDWeek 2021 conference — compared the vaccine to a placebo shot in 5,782 volunteers aged 65 years and older in the U.S. through a single RSV season. Cases of lower respiratory tract disease caused by RSV were reduced by 80% in participants who received the vaccine when compared to a placebo, and cases of any RSV-related respiratory infection were reduced by 70%.

Investigators also evaluated immune response in vaccine recipients, who experienced a "substantial increase" in RSV neutralizing antibodies when measured 14 days after their single shots of the vaccine, J&J said.

Last week, the company announced it was starting the Phase 3 EVERGREEN trial, positive results from which could help it win Food and Drug Administration approval. The study will enroll 23,000 people aged 60 and older, and measure prevention of RSV-related lower respiratory tract disease as its primary goal.

The trial puts J&J just weeks behind Pfizer, which will evaluate its RSV vaccine in the RENOIR trial that aims to enroll 30,000 people and generate data in 2022. GSK, meanwhile, has begun a Phase 3 trial to study safety and immune response, but hasn't announced plans for a large efficacy trial.

Bavarian Nordic has reported efficacy of 79% in a human challenge study and expects to provide further details on its Phase 3 plans before the end of the year.

In a Sept. 7 note to clients, Porges predicted that GSK will win 27% of the market, while Pfizer and J&J will get 20% and 16%, respectively.

Follow on Twitter

Five biotechs are set to price new stock offerings in what could be the most active week for IPOs since July. Two others, LianBio and Xilio Therapeutics, just joined the queue. 

Subscribe to BioPharma Dive to get the must-read news & insights in your inbox.

Topics covered: Pharma, biotech, FDA, gene therapy, clinical trials, drug pricing and much more.

Discover announcements from companies in your industry.

Executives at Amylyx Pharmaceuticals said that based on the agency's recent feedback, they will soon ask for approval of AMX0035 — a change of plans from earlier this year. 

Five biotechs are set to price new stock offerings in what could be the most active week for IPOs since July. Two others, LianBio and Xilio Therapeutics, just joined the queue. 

The free newsletter covering the top industry headlines

Topics covered: Pharma, biotech, FDA, gene therapy, clinical trials, drug pricing and much more.

The free newsletter covering the top industry headlines

Topics covered: Pharma, biotech, FDA, gene therapy, clinical trials, drug pricing and much more.

Coronavirus NY: Northwell Health's new COVID PCR tests will be faster, cheaper

PharmaLive 05 October, 2021 - 05:26pm

COVID NY: Northwell Health's new PCR tests could be a game changer

United Airlines put in one of the first COVID vaccine mandates, and now it is firing nearly 600 employees who have refused to comply with it.

Brian Laundrie's sister, Cassie, spoke out exclusively to ABC News in the wake of her brother's disappearance.

Coronavirus NY: Northwell Health's new COVID PCR tests will be faster, cheaper

MarketWatch 05 October, 2021 - 05:26pm

COVID NY: Northwell Health's new PCR tests could be a game changer

United Airlines put in one of the first COVID vaccine mandates, and now it is firing nearly 600 employees who have refused to comply with it.

Brian Laundrie's sister, Cassie, spoke out exclusively to ABC News in the wake of her brother's disappearance.

RSV Adult Vaccine Candidate Provides 80% Protection

PrecisionVaccinations 04 October, 2021 - 12:09pm

The Janssen Pharmaceutical Companies of Johnson & Johnson announced on October 2, 2021, that its investigational respiratory syncytial virus (RSV) vaccine candidate was highly effective in protecting against lower respiratory tract disease (LRTD) caused by RSV.

The Janssen RSV vaccine candidate demonstrated 80% efficacy (CI, 52.2-92.9%) in adults aged 65 and older.

Following an initial proof-of-concept study with Janssen’s investigational RSV adult vaccine (Ad26.RSV.preF component only) in a human challenge study, Janssen combined Ad26.RSV.preF with a prefusion F (preF) protein for induction of a more optimal immune response.

This combination single-dose regimen was evaluated in the Phase 2b CYPRESS study, which enrolled 5,782 participants across 40 sites in the United States followed through a single RSV season.

There is no preventive vaccine or broadly available antiviral treatment for RSV, a highly contagious, potentially life-threatening respiratory virus affecting more than 64 million people worldwide in a typical year across all age groups.

“RSV remains a major global public health concern and a cause of serious respiratory illness in all age groups,” stated Ann R. Falsey, M.D., Professor of Medicine, University of Rochester School of Medicine and presenting author, in a press release.

“The positive efficacy results from the CYPRESS study reinforce the potential of this investigational RSV vaccine in preventing serious disease resulting from RSV in older adults.”

In September 2019, the U.S. Food and Drug Administration granted Breakthrough Therapy Designation for Janssen’s investigational RSV adult vaccine to prevent LRTD caused by RSV in adults aged 60 years or older.

Janssen is the Pharmaceutical Company of Johnson & Johnson, located in New Jersey, working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart.

Precision Vax LLC websites do not provide medical advice, diagnosis, treatment, or prescriptions. Read our terms of use for more info.

Health Stories

JCPenney